Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02553915 · ClinicalTrials.gov registry record · Phase 2
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT02553915: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02553915 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02553915, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This project aims to evaluate whether a dose-response relationship exists between dose of polyunsaturated fatty acids (PUFA), delivered as eicosapentaenoic acid (EPA), and change in markers of inflammation, and whether these effects differ from placebo. A key secondary aim is to evaluate the antidepressant effectiveness of EPA in overweight adult outpatients with current major depressive disorder (MDD). To address these aims, the project will use a four-arm, randomized, parallel-group, placebo-controlled design comparing placebo versus three doses of EPA (1 gm/day, 2 gm/day, or 4 gm/day) administered over 12 weeks. The study is to be conducted at two sites: Emory University School of Medicine, and Massachusetts General Hospital. Eligible participants will be between the ages of 18-80 who have current MDD, are overweight, and who demonstrate peripheral inflammation, defined as an high sensitivity C-reactive protein (hs-CRP) level ≥ 3 mg/L. The primary outcome will be change in plasma interleukin-6 (IL-6) levels and/or mitogen-stimulated peripheral blood mononuclear cells (PBMC) Tumor Necrosis Factor-alpha (TNF-α) expression levels in EPA- versus placebo-treated participants. The results of this investigation are intended to be used to design and power a larger definitive test of the efficacy and biological effects of EPA in patients with major depressive disorder.
Interventions
- OTHER Placebo
- DRUG EPA 1 g/day
- DRUG EPA 2 g/day
- DRUG EPA 4 g/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2015-12 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02553915
The ClinicalTrials.gov registry entry for NCT02553915 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02553915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02553915 about?
NCT02553915 is a clinical study titled "Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach". This project aims to evaluate whether a dose-response relationship exists between dose of polyunsaturated fatty acids (PUFA), delivered as eicosapentaenoic acid (EPA), and change in markers of inflammation, and whether these effects differ from placebo. A key secondary aim is to evaluate the antidep...
What is the current status of trial NCT02553915?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2015-12. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT02553915?
The interventions under investigation include: Placebo (OTHER), EPA 1 g/day (DRUG), EPA 2 g/day (DRUG), EPA 4 g/day (DRUG).
Who is sponsoring clinical trial NCT02553915?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.